| 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 3 | | 第四章 | 股东和股东大会 | 6 | | 第五章 | 董事会 | 23 | | 第六章 | 总裁及其他高级管理人员 | 31 | | 第七章 | 监事会 | 32 | | 第八章 | 财务会计制度、利润分配和审计 | 35 | | 第九章 | 通知和公告 | 40 | | 第十章 | 合并、分立、增资、减资、解散和清算 | 41 | | 第十一章 | 修改章程 | 45 | | 第十二章 | 附则 | 45 | 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行 为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国 证券法》（以下简称《证券法》）和其他有关规定，制订本章程。 第二条 重庆智飞生物制品股份有限公司系依照《中华人民共和国公司 法》和其他有关规定成立的股份有限公司（以下简称"公司"）。 公司由重庆智飞生物制品有限责任公司于二〇〇九年九月依法整体变更 设立，在重庆市市场监督管理局注册登记，取得营业执照 ...

Financial Performance - In 2023, the company achieved a revenue of 52.918 billion yuan and a net profit of 8.07 billion yuan, with total tax contributions reaching 7.692 billion yuan[2]. - The company reported a significant increase in revenue, achieving a total of RMB 5.2 billion in 2023, representing a year-on-year growth of 25%[13]. - The company's operating revenue for 2023 was ¥52.92 billion, an increase of 38.30% compared to ¥38.26 billion in 2022[18]. - Net profit attributable to shareholders for 2023 was ¥8.07 billion, up 7.04% from ¥7.54 billion in 2022[18]. - The net cash flow from operating activities reached ¥8.99 billion, a significant increase of 352.30% from ¥1.99 billion in 2022[18]. - The company reported a basic earnings per share of ¥3.3624 for 2023, an increase of 7.04% from ¥3.1412 in 2022[18]. - The company achieved a revenue of 52.918 billion yuan in 2023, representing a year-on-year growth of 38.30%[53]. - The net profit attributable to shareholders reached 8.070 billion yuan, an increase of 7.04% compared to the previous year[53]. - The company reported a total of 6,545 employees at the end of the reporting period, with 3,990 in sales, 1,216 in production, and 927 in technical roles[142]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 8 yuan per 10 shares, totaling 1.915 billion yuan, which will bring cumulative cash dividends since listing to 6.839 billion yuan[4]. - The board of directors has approved a dividend payout of 0.5 CNY per share, signaling confidence in future growth prospects[121]. - The company implemented a cash dividend policy, distributing 8.00 CNY per 10 shares, totaling 1,915,031,797.60 CNY, which represents 100% of the total profit distribution[148]. Research and Development - The company has made significant progress in clinical research for multiple self-developed products in Anhui[2]. - The company is focused on integrating internal and external resources to acquire cutting-edge research technologies and product pipelines[2]. - The company is committed to addressing the uncertainties in product development and sales through effective risk management strategies[6][7]. - The company has established three major research and production bases and an innovation product incubation center to enhance its R&D capabilities and product development[36]. - The company has developed nine major technology R&D platforms, covering various vaccine development paths, which strengthens its core R&D capabilities[37]. - The company has increased its R&D investment to enhance quality control and service levels, ensuring public health and driving company growth[33]. - In 2023, the company's R&D investment reached CNY 1.345 billion, accounting for approximately 130.81% of self-developed product revenue, a year-on-year increase of 20.82%[54]. - The number of R&D personnel increased to 927 in 2023, up 14.87% from 807 in 2022[75]. Product Development and Innovation - New product development includes the launch of a recombinant COVID-19 vaccine, which has shown a 95% efficacy rate in clinical trials[12]. - The company plans to introduce two new vaccines in 2024, focusing on infectious diseases prevalent in the region[14]. - The company is actively pursuing product innovation, with a focus on developing multi-valent and innovative vaccines to meet growing public health needs[29]. - The company is developing multiple vaccines, including a recombinant hepatitis B vaccine and a bivalent hand-foot-mouth disease vaccine, with several candidates expected to enter clinical trials in 2024-2025[43]. - The company has several projects in advanced clinical trial stages, including the lyophilized recombinant tuberculosis vaccine and the four-valent norovirus vaccine[42]. Market Expansion and Partnerships - The company has deepened international cooperation, renewing agreements with Merck in January and partnering with GlaxoSmithKline in October for vaccine commercialization[2]. - The company is actively pursuing market expansion, targeting a 15% increase in market share in the Asia-Pacific region by the end of 2024[14]. - The company is actively pursuing international partnerships and collaborations to enhance vaccine accessibility and affordability globally[60]. - The company signed a supply, distribution, and co-promotion agreement with Merck on January 21, 2023, for HPV vaccines and pentavalent rotavirus vaccines, with a total procurement amount exceeding RMB 100 billion[188]. - On October 8, 2023, the company entered into an exclusive distribution and joint promotion agreement with GSK for the recombinant shingles vaccine, with GSK becoming the exclusive partner for any RSV vaccine development in the cooperation area[188]. Compliance and Governance - The company has developed a comprehensive internal control system to ensure compliance with relevant laws and regulations[103]. - The company has a governance structure that includes a board of directors, supervisory board, and specialized committees, ensuring effective checks and balances[104]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring clear ownership and accountability[108]. - The company has established a standard performance evaluation and incentive mechanism, aligning with its operational goals and development status[106]. - The company has not engaged in any major related party transactions during the reporting period[184]. Environmental Responsibility and Social Contributions - The company has committed to 100% compliant waste discharge to prevent environmental pollution[172]. - The company has implemented strict management of hazardous waste, ensuring proper storage and disposal through qualified third-party organizations[173]. - The company has participated in 14 charitable donation projects, with a total donation amount exceeding 42 million yuan, including cash donations and medical supplies[176]. - The company has established a "Rural Revitalization Charity Fund" to support the construction of 100 village health clinics in Guangxi Province, enhancing local medical services[177]. - The company emphasizes the importance of environmental protection and employee health, continuously exploring energy-saving and resource-conserving operational models[175].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于 2024 年 4 月 19 日 在公司会议室以现场结合通讯表决的方式召开第五届董事会第十七次会议、第五 届监事会第十一次会议，审议通过了《2023 年度利润分配预案及 2024 年中期分 红提案》，现将具体情况公告如下： 证券代码：300122 证券简称：智飞生物 公告编号：2024-24 重庆智飞生物制品股份有限公司 关于 2023 年度利润分配预案及 2024 年中期分红提案的公告 一、2023 年度利润分配预案的基本情况 根据信永中和会计师事务所（特殊普通合伙）出具的 XYZH/2024BJAA11B0193 号《重庆智飞生物制品股份有限公司 2023 年度审计报告》，截至 2023 年 12 月 31 日，公司实现归属于母公司所有者的净利润为 8,069,868,204.15 元。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》及《公司章程》的相关规定，为贯彻"以投资者为本"的上市公司发 展理念，深入践行"质量回报双提升 ...

证券代码：300122 证券简称：智飞生物 公告编号：2024-19 重庆智飞生物制品股份有限公司 第五届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会于 2024 年 4 月 9 日以电子邮件的方式向董事发出通知。 2、本次会议于 2024 年 4 月 19 日 10:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的董事 9 人，实际出席并参加表决的董事 9 人。 4、本次会议由公司董事长蒋仁生先生主持，公司监事、高级管理人员列席 了本次会议。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件及公司章程的规定。 二、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： 1、审议通过了《2023 年度总裁工作报告》 表决结果：赞成 9 票，反对 0 票，弃权 0 票，本议案获得通过。 2、审议通过了《2023 年年度报告》及《2023 年年度报告摘要》 公司《2023 年年度报告》及《2023 年年度报告摘要》的编制程序符 ...

证券代码：300122 证券简称：智飞生物 公告编号：2024-20 重庆智飞生物制品股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会于 2024 年 4 月 9 日以电子邮件的方式向监事发出通知。 2、本次会议于 2024 年 4 月 19 日 11:00 在公司会议室以现场表决方式召开。 3、本次会议应出席并参加表决的监事 3 人，实际出席并参加表决的监事 3 人。 4、本次会议由公司监事会主席徐海萍女士主持。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和公司章程的规定。 二、监事会会议审议情况 经过认真审议，本次会议形成了如下决议： 1、审议通过了《2023 年年度报告》及《2023 年年度报告摘要》 经审核，监事会认为：董事会编制和审核公司 2023 年年度报告及摘要的程 序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容详见当日刊登在中国 ...

证券代码：300122 证券简称：智飞生物 公告编号：2024-28 重庆智飞生物制品股份有限公司董事会 2024 年 4 月 23 日 1 重庆智飞生物制品股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）获本公司职工代表 监事张玉女士的通知，其已于近期完成了更名并收到了户口登记机关发放的证 件，现将相关变更情况公告如下： 关于职工代表监事更名的公告 原姓名"张郁"正式变更为"张玉"。 特此公告 ...

证券代码：300122 证券简称：智飞生物 公告编号：2024-23 重庆智飞生物制品股份有限公司 关于续聘公司 2024 年度审计机构的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于 2024 年 4 月 19 日分 别召开第五届董事会第十七次会议、第五届监事会第十一次会议，审议通过了《关 于续聘公司 2024 年度审计机构的议案》，同意续聘信永中和会计师事务所（特殊 普通合伙）（以下简称"信永中和"）为公司 2024 年度审计机构，聘期一年，自公 司 2023 年年度股东大会审议通过之日起生效。本事项尚需提交公司 2023 年年度 股东大会审议。 本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国有企 业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。现将具 体情况公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青先生 截止 2 ...

一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 1、基本信息 首席合伙人：谭小青先生 重庆智飞生物制品股份有限公司 董事会审计委员会对会计师事务所 2023 年度 履职情况评估及履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》和《重庆智飞生物制品股 份有限公司章程》等规定和要求，重庆智飞生物制品股份有限公司（以下简称"公 司"）董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将公司 董事会审计委员会对信永中和会计师事务所（特殊普通合伙）（以下简称"信永 中和"）2023 年度履职评估及履行监督职责的情况汇报如下： 截止 2023 年 12 月 31 日，信永中和合伙人（股东）245 人，注册会计师 1656 人。签署过证券服务业务审计报告的注册会计师人数超过 660 人。 信永中和 2022 年度业务收入为 39.35 亿元，其中，审计业务收入为 29.34 亿元，证券业务收入为 8.89 亿元。2022 年 ...

证券代码：300122 证券简称：智飞生物 公告编号：2024-27 重庆智飞生物制品股份有限公司 关于举行2023年度业绩网上说明会的公告 欢迎广大投资者积极参与。 特此公告 重庆智飞生物制品股份有限公司董事会 2024 年 4 月 23 日 重庆智飞生物制品股份有限公司（以下简称"公司"）《2023年年度报告》 已于2024年4月23日公布于中国证监会指定信息披露网站巨潮资讯网。为进一步 解读公司年度报告，帮助广大投资者更深入全面地了解公司经营情况，公司定于 2024年5月14日（星期二）15:00-17:00在全景网举行2023年度业绩网上说明会。 本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆"全景路演" （http://rs.p5w.net）参与会议，与公司管理层互动、沟通。 出席本次年度业绩说明会的人员情况如下：董事长兼总裁蒋仁生先生、董 事会秘书秦菲先生、财务总监李振敬先生、独立董事袁林女士。 为充分尊重投资者，广泛听取投资者的意见和建议，现就公司2023年度业绩 说明会提前向投资者公开征集问题，提问通道自发出公告之日起开放。投资者可 于2024年5月14日（星期二）12:00前通过访 ...

Financial Performance - The company's revenue for Q1 2024 was ¥11,395,682,504.71, representing a 2.00% increase compared to ¥11,172,773,125.45 in the same period last year[2] - Net profit attributable to shareholders decreased by 28.26% to ¥1,457,744,248.17 from ¥2,032,024,553.16 year-on-year[2] - The company's basic earnings per share fell by 28.07% to ¥0.6090 from ¥0.8467 in the same period last year[2] - Net profit for Q1 2024 was ¥1,457,744,248.17, a decrease of 28.2% from ¥2,032,024,553.16 in Q1 2023[18] - Basic and diluted earnings per share for Q1 2024 were both ¥0.6090, down from ¥0.8467 in Q1 2023[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥4,273,676,599.75, a decline of 310.92% compared to -¥1,040,028,831.23 in the previous year[9] - Total cash inflow from operating activities was ¥8,387,064,252.28, while total cash outflow was ¥12,660,740,852.03[20] - Cash flow from operating activities showed a net outflow of ¥4,273,676,599.75, compared to a net outflow of ¥1,040,028,831.23 in the previous year[20] - Cash and cash equivalents decreased by ¥3,368,736,087.79 in Q1 2024, compared to an increase of ¥176,160,972.80 in Q1 2023[21] - Cash and cash equivalents at the end of Q1 2024 stood at ¥2,970,554,147.12, up from ¥2,791,849,824.14 at the end of Q1 2023[21] - Cash inflow from financing activities was ¥4,097,486,152.00, significantly higher than ¥2,866,915,531.74 in Q1 2023[20] - Cash outflow for repaying debts was ¥2,629,363,041.00, compared to ¥1,350,079,178.00 in the previous year[20] - The company received ¥47,029,975.63 from other operating activities, an increase from ¥32,775,487.78 in Q1 2023[20] - The company reported a total cash outflow from investment activities of ¥236,232,912.39, compared to ¥270,977,272.24 in Q1 2023[20] Assets and Liabilities - The total assets increased by 6.64% to ¥53,568,800,848.87 from ¥50,232,190,314.35 year-on-year[3] - The company's total liabilities increased to CNY 20,905,005,959.51 from CNY 18,726,109,501.03, indicating higher leverage[15] - The total current assets amounted to CNY 45,731,274,065.90, an increase from CNY 42,514,016,731.06 at the beginning of the period[14] - Cash and cash equivalents decreased to CNY 2,971,776,140.82 from CNY 6,340,512,228.61[14] - Accounts receivable increased to CNY 30,029,039,075.81 from CNY 27,058,579,283.73, indicating a growth of approximately 7.3%[14] - Non-current assets include intangible assets valued at CNY 311,157,949.19, slightly down from CNY 317,684,334.76[14] Equity and Shareholder Information - The total equity attributable to shareholders increased by 3.67% to ¥32,663,794,889.36 from ¥31,506,080,813.32 year-on-year[3] - The company reported a total of 289,893,375 shares held by major shareholder Jiang Rensheng, representing a significant portion of the equity[12] - The top ten shareholders include institutional investors holding a combined total of 16,882,123 shares, accounting for 0.70% of total equity[12] - The company's total equity increased to CNY 32,663,794,889.36 from CNY 31,506,080,813.32, reflecting strong financial health[16] - Unappropriated profits grew to CNY 29,315,860,286.55 from CNY 27,858,116,038.38, showing retained earnings improvement[16] Operational Expenses - The company reported a significant increase in management expenses by 38.95% to ¥110,948,123.03, mainly due to higher fixed costs[8] - Operating costs for the same period were CNY 9,323,352,619.26, up from CNY 8,596,876,197.85, indicating a rise in expenses[17] - Research and development expenses for Q1 2024 were CNY 234,083,332.08, up from CNY 213,960,021.59, highlighting a focus on innovation[17] - The company has ongoing research and development efforts, with development expenditures recorded at CNY 1,039,736,765.37[14] Market Outlook and Strategy - The financial report indicates a stable outlook for the upcoming quarters, with a focus on maintaining liquidity and managing receivables effectively[12] - The company is exploring market expansion strategies, although specific details were not disclosed in the report[12]